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Abstract
Valvular heart disease is associated with an increased thromboembolic risk. Impaired fibrinolysis was reported in severe aortic 
stenosis (AS). Little is known about fibrinolysis in mitral stenosis (MS). We sought to compare fibrinolysis impairment in AS 
and MS. We studied 121 individuals scheduled for elective aortic valve (AV) or mitral valve (MV) surgery for AS (n = 76) 
or MS (n = 45), in order to compare fibrinolysis impairment. Fibrinolytic capacity was assessed by determination of clot 
lysis time  (t50%) and fibrinolysis inhibitors, including plasma plasminogen activator inhibitor-1 (PAI-1) antigen (PAI-1:Ag) 
and activity, thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity. Prolonged  t50% (+ 29%), elevated TAFI 
activity (+ 12%), TAFI:Ag (+ 21%), and PAI-1:Ag (+ 84%) were observed in patients with MS, compared with those with 
AS.  t50% Correlated with mean and maximal MV gradients (r = 0.43, p < 0.0001 and r = 0.39, p < 0.0001, respectively), but 
not with AV gradients. Mean and maximal MV gradients correlated with TAFI activity and PAI:Ag. Patients with perma-
nent atrial fibrillation (AF; 35 with MS and 5 with AS) had longer  t50% (by 22%, p = 0.0002) and higher PAI-1:Ag (by 74%, 
p < 0.0001) than the remainder. In the whole group, postoperative drainage volumes correlated inversely with PAI-1:Ag 
(r = − 0.22, p = 0.02). MS is associated with more pronounced impairment of global fibrinolytic capacity than AS at the 
stage of surgical intervention, which is in part driven by AF. Our findings suggest that hypofibrinolysis might be implicated 
in the progression of MS and its thromboembolic complications.
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Highlights
• Valvular heart disease is associated with increased 
thromboembolic risk
• Degenerative mitral stenosis is associated with more pro-
nounced impairment of global fibrinolytic capacity than 
aortic stenosis at the stage of surgical intervention
• Atrial fibrillation contributes to fibrinolysis impairment 
in mitral stenosis
• The role of fibrinolysis in pathology and progression of 
valvular disorders and their thromboembolic complica-
tions needs to be investigated
Introduction
Valvular heart disease (VHD) remains a key public health 
problem worldwide. Degenerative aortic stenosis (AS) is 
common in developed countries, and its prevalence increases 
with age [1]. The mechanisms involved in the development 
of AS resemble the ones involved in the development of 
coronary artery atherosclerosis [2]. Mitral stenosis (MS), 
on the other hand, is related to the structural abnormality of 
the mitral valve (MV) apparatus, and can be a distant sequel 
of rheumatic fever, or may result from severe non-rheumatic 
degenerative mitral annular calcification [3]. Mitral annu-
lar calcification is present in up to 10% of elderly patients, 
and MS develops in 1–2% of this group [3, 4]. It has been 
shown that atherosclerotic risk factors are associated with 
mitral annular calcification leading to MS [5]. Based on the 
2015 Society of Thoracic Surgeons Adult Cardiac Surgery 
Database Report, isolated aortic valve replacement (AVR) 
was performed in 21,921 patients, while isolated mitral valve 
replacement (MVR) in 5180 cases in United States alone [6].
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Blood coagulation leads to thrombin-mediated conver-
sion of fibrinogen to fibrin. Fibrin clots composed of tightly 
packed thin fibers with small pores are relatively resistant 
to lysis [7] and such prothrombotic clot phenotype has been 
shown in multiple disease states, such as myocardial infarc-
tion (MI) [8] or ischemic stroke [9]. Although the research 
on AS is most frequently focused on calcification, in 2013 
our group documented impaired fibrinolysis in 74 patients 
with severe AS, evidenced by prolonged plasma fibrin clot 
lysis time (CLT) and increased plasma plasminogen activa-
tor inhibitor-1 (PAI-1), as compared to controls [10]. CLT 
was positively correlated with the valve leaflet thickness, 
the degree of valve calcification, valvular fibrin and PAI-1 
expression [10].
Impaired fibrinolysis is usually driven by increased levels 
and/or enhanced function of its inhibitors. PAI-1 is a key 
regulator of fibrinolysis that controls the plasmin-generating 
activity of tissue-type plasminogen activator and urokinase-
type plasminogen activator [11]. PAI-1 expression is found 
in as many as in 69% of the human AS valves [12]. Another 
fibrinolysis inhibitor, thrombin activatable fibrinolysis inhib-
itor (TAFI), which cleaves C-terminal lysine and arginine 
residues from partially degraded fibrin, thereby attenuating 
efficient plasminogen activation, has also been shown to be 
elevated in AS patients [13]. Clinical relevance of varying 
levels of circulating fibrinolysis inhibitors in VHD is unclear 
due to the paucity of data. It has been reported in a study on 
28 individuals with severe MS that blood coagulation activa-
tion and fibrinolytic activity assessed using plasma D-dimer 
levels were increased in MS, compared with controls [14]. 
Marin et al. showed impaired fibrinolysis in 24 MS patients, 
compared with 18 controls, as reflected by elevated PAI-1 
(both in patients with atrial fibrillation [AF] and in sinus 
rhythm), without assessment of the overall fibrinolytic 
plasma capacity [15].
To the best of our knowledge, there are no studies 
comparing the functional status of the fibrinolytic system 
between different degenerative valvular disorders. We 
sought to compare the fibrinolytic system activity in patients 
with late-stage degenerative AS (a degenerative valvular 
disease with high-velocity flow) with patients with degen-
erative MS (a group with a stenotic valvular condition with 
lower flow velocity). A multimodal approach was employed, 
which included assessment of global fibrinolytic capacity 
and fibrinolysis inhibitors.
Methods
Patients
From February 2013 to April 2014 we recruited 121 indi-
viduals scheduled for elective valvular surgery due to 
degenerative AS or MS. All patients were assessed preopera-
tively by a local ‘heart team’, and the surgery was conducted 
according to the ‘heart team’ indication.
The exclusion criteria were: rheumatic etiology of VHD 
(to exclude the confounding effect of inflammation), ongo-
ing infective endocarditis, combined AV and MV replace-
ment procedure, emergency surgery, root dilation requiring 
aortic surgery, prior cardiac surgery, MI or percutaneous 
coronary intervention (PCI) followed by dual antiplatelet 
therapy within 1 month prior to enrolment, renal failure 
(serum creatinine > 177 µmol/L), prior bleeding diathesis, 
arterial or venous thromboembolic events within the previ-
ous 6 months, known cancer, any chronic inflammatory dis-
ease. Concomitant CABG, as well as current anticoagulant 
therapy were not used as exclusion criteria. Necessity for 
concomitant valve repair (due to secondary mitral regurgita-
tion [MR] in AS, and tricuspid regurgitation [TR] in MS) 
was not used as an exclusion criterion. In-hospital cardio-
vascular death was defined as death due to cardiovascular 
diseases, occurring during the same hospitalization.
Echocardiography was performed by an experienced car-
diologist on a Toshiba APLIO 80 (Toshiba, Tokyo, Japan) 
ultrasound machine. AS was defined as severe when mean 
transvalvular pressure gradient was ≥ 40 mmHg and/or AV 
area was ≤ 1 cm2. All enrolled AS patients had to be symp-
tomatic. MS was deemed a surgical indication in a symp-
tomatic patient when MV area was ≤ 1.5 cm2 [16]. Valve 
regurgitation was graded with color Doppler flow analysis 
using the following scale: none (0), trivial (1), mild (2), 
moderate (3) and severe (4). If a patient was on oral vita-
min K antagonist (VKA) therapy prior to operation, it was 
stopped 5 days before admission, and perioperative bridging 
with low molecular weight heparin (LMWH) was initiated. 
A regimen of 1 mg/kg enoxaparin twice daily was applied 
in all cases.
The study was performed in accordance with the Declara-
tion of Helsinki, and received approval of the Jagiellonian 
University Ethical Committee. All patients provided their 
written informed consent.
Operative management
All patients underwent standardized anaesthesia and 
received median sternotomy. Cardio-pulmonary bypass 
(CPB) was performed at moderate hypothermia (esopha-
geal temperature, 32 °C) using a non-pulsatile roller pump 
(Jostra Medizintechnik AG, Hirrlingen, Germany) and a 
40 µm arterial blood filter (Jostra Medizintechnik AG, Hir-
rlingen, Germany), with blood flow at 2.0–2.4 l/min/m2, 
and mean arterial pressure at 40–60 mmHg. Aortic valve 
anatomy was confirmed intraoperatively by a surgeon in AS. 
Tranexamic acid was administered in two doses (20 mg/kg 
i.v. after sternotomy, and 20 mg/kg i.v. after the end of CPB) 
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in all cases. All patients were transferred to the intensive 
care unit (ICU) for postoperative ventilation, and extubated 
following standard criteria.
Laboratory investigations
Fasting blood samples were collected from an antecubital 
vein with minimal stasis at 6–8 a.m. on the day of surgery, 
prior to the onset of any surgery-related procedures. Plasma 
samples were centrifuged within 30 min of collection, fro-
zen, and stored in aliquots at − 80 °C until assayed. Rou-
tine methods were used for standard laboratory parameters. 
Commercially available enzyme-linked immunoabsorbent 
assays were used to determine plasma PAI-1 antigen (PAI-
1:Ag; Hyphen, Neuville, France), PAI-1 activity (PAI-1:Act; 
American Diagnostica, Stamford, CT, USA) and TAFI anti-
gen (Stachrom TAFI, Diagnostica Stago, Asnieres, France). 
Plasma TAFI activity was measured by a chromogenic 
assay using the ACTICHROME® Plasma TAFI Activity 
Kit (American Diagnostica, Stamford, CT, USA). We also 
measured activated and inactivated TAFI antigen in plasma 
(TAFIa/TAFIai; Diagnostica Stago, Asnieres, France), 
plasmin-α-2-antiplasmin complexes (PAP; DRG Instru-
ments, Marburg, Germany) and platelet factor 4 (PF4; R&D 
Systems, Minneapolis, MN, USA).
Clot lysis assay
Plasmin-mediated fibrinolysis in the presence of recom-
binant tissue plasminogen activator (rtPA) (Boehringer 
Ingelheim, Ingelheim, Germany) was evaluated as previ-
ously described [17, 18]. Briefly, 100 µL of citrated plasma 
was diluted with 100 µL of a buffer (0.05 mol/L Tris–HCl, 
0.15 mol/L NaCl, pH 7.4), containing 20 mmol/L calcium 
chloride, 1 U/mL human thrombin (Sigma-Aldrich), and 
14 µmol/L rtPA. The assembly kinetics was monitored by 
spectrophotometry at 405 nm, in duplicate. Lysis time was 
defined as the time required for a 50% decrease in fibrin clot 
absorbance  (t50%) and was chosen as a marker of the clot 
susceptibility to fibrinolysis. The interassay and intraassay 
coefficients of variation were below 6%.
Statistical analysis
The study was powered to have an 80% chance of detecting 
a 25% intergroup difference in  t50% using a p-value of 0.05, 
based on the values of these parameters in the published arti-
cle [19]. In order to demonstrate such a difference or greater 
in this variable, 20 patients were required in each group. The 
patient enrollment continued until a sufficient number of MS 
patients was met. Continuous variables were presented as 
mean ± standard deviation (SD) or median and quartiles, as 
appropriate. Categorical variables were presented as counts 
and percentages. The Shapiro–Wilk test was used to test 
the normality of continuous variables. To examine the dif-
ferences between two independent groups Student’s t-test 
or Mann–Whitney U test were used, as appropriate. The χ2 
test or Fischer’s exact test was used for categorical variables. 
To assess linear correlation between variables, the Pearson 
correlation coefficient (Pearson’s r) for normally distributed 
variables or Spearman’s rank correlation coefficient (Spear-
man’s rho) for non-normally distributed variables were cal-
culated. Linear regression was used to test the influence of 
MS, AF and VKA use on  t50%. These variables were tested 
in simple regression, and then put together into a multiple 
model. Statistical analysis was performed with STATIS-
TICA 12.0 (StatSoft, Tulsa, OK). Two sided p-values < 0.05 
were considered statistically significant.
Results
Patient characteristics
A total of 97 patients (46% men) with preserved left ven-
tricular function were included in the study. Seventy-six 
patients (63%) underwent surgery for AS (26 had a bicuspid 
valve), and 45 (37%) for MS, and the clinical and echocar-
diographic characteristics of both groups are presented in 
Table 1. MS patients had lower BMI, were more often diag-
nosed with AF, had a history of stroke and were treated 
with VKA, while AS patients more often had hypertension, 
hypercholesterolemia and CAD, and received aspirin, ACEI 
and statins. MS patients were in higher New York Heart 
Association class, had mildly decreased left ventricular sys-
tolic function, and demonstrated higher values of INR and 
APTT (Table 1.).
Operative and postoperative characteristics are presented 
in Table 2. MS patients required a shorter aortic cross-
clamping, and more frequently received a mechanical valve, 
but did not differ from AS patients in terms of re-exploration 
for bleeding, transfusions or early mortality.
Fibrinolysis
In MS, t50% was prolonged (+ 29%), TAFI activity (+ 12%), 
TAFI:Ag (+ 21%), and PAI-1:Ag (+ 69%) were elevated, 
when compared with AS subjects (Fig. 1; Table 2.). No dif-
ferences in fibrinogen, d-dimer or PAP levels were noted. 
In the whole cohort (n = 121),  t50%, TAFI activity and PAI-
1:Ag positively correlated with MV (but not AV) gradients 
(Fig. 2.).  t50% correlated also with MR degree (r = 0.29, 
p = 0.001).
In all patients (n = 121), there was a positive association 
between  t50% and PAI-1:Ag (r = 0.21, p = 0.02), and negative 
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between  t50% and PAP (r = − 0.45, p < 0.0001). PAI-1:Ag 
and PAP correlated with BMI (r = 0.28, p = 0.002 and 
r = 0.22, p = 0.01, respectively).
Preoperative APTT correlated inversely with PAI-
1:Ag (r = − 0.20, p = 0.03) and TAFIa/TAFIai (r = − 0.19, 
p = 0.04).
Table 1  Baseline patient characteristics
Bold values used to visually identify significant p-values (<0.05)
Data shown as mean ± SD or as median (IQR), or number (percentage)
ACEI angiotensin-converting enzyme inhibitors, Ag antigen, APTT activated partial thromboplastin time, BMI body mass index, LVEF left ven-
tricular ejection fraction, INR international normalized ratio, NYHA New York Heart Association. The p-values refers to the comparison between 
patients with aortic stenosis and mitral stenosis
Variable Normal reference values 
(where applicable)
All patients (n = 121) Valve stenosis p Value
Aortic (n = 76) Mitral (n = 45)
Age, years 65 (61–74) 66 (61–74) 64 (59–69) 0.06
Male sex, n (%) 57 (47) 40 (53) 17 (38) 0.11
BMI, kg/m2 27.4 ± 4.8 28.2 ± 4.6 26.3 ± 4.8 0.03
Diabetes mellitus, n (%) 39 (32) 26 (34) 13 (29) 0.55
Arterial hypertension, n (%) 94 (78) 67 (88) 27 (60) 0.0003
Persistent atrial fibrillation, n (%) 40 (33) 5 (7) 35 (78) < 0.0001
Paroxysmal atrial fibrillation, n (%) 5 (4) 5 (7) 0 (0) 0.51
LVEF ≤ 40%, n (%) 16 (13) 9 (12) 7 (16) 0.37
Hypercholesterolemia, n (%) 85 (70) 59 (78) 26 (58) 0.02
Current smoking, n (%) 9 (7) 5 (7) 4 (9) 0.47
History of smoking, n (%) 28 (23) 16 (21) 12 (27) 0.48
Coronary artery disease, n (%) 49 (41) 39 (51) 10 (22) 0.002
Previous MI, n (%) 19 (16) 15 (20) 4 (9) 0.09
Previous stroke, n (%) 7 (6) 1 (1) 6 (13) 0.01
NYHA functional class 2 (2–3) 2 (2–3) 3 (2–3) 0.006
Medication
 Aspirin, n (%) 61 (50) 50 (66) 11 (24) < 0.0001
 VKAs, n (%) 46 (38) 10 (13) 36 (80) < 0.0001
 ACEI, n (%) 76 (63) 53 (70) 23 (51) 0.04
 β-Blocker, n (%) 97 (80) 65 (86) 32 (71) 0.05
 Statin, n (%) 84 (69) 59 (78) 25 (56) 0.01
Laboratory variables
 INR 0.90–1.20 1.04 (0.99–1.10) 1.02 (0.98–1.07) 1.08 (1.03–1.18) < 0.0001
 APTT, s 25.9–36.6 26.5 (24.8–28.9) 26.0 (24.5–28.2) 27.9 (25.6–30.2) 0.009
 Fibrinogen, g/L 1.5–4.0 3.3 (2.8–4.0) 3.2 (2.8–3.9) 3.4 (2.6–4.2) 0.95
 D-dimer, ng/mL < 500 450 (311–591) 439 (305–556) 488 (341–617) 0.24
 Creatinine, µmol/L 62–106 86 (76–102) 84 (77–96) 90 (75–105) 0.45
Echocardiography
 Aortic valve pressure gradient
  Maximal (mmHg) 67 (14–87) 79 (65–97) 7 (5–11) < 0.0001
  Mean (mmHg) 42 (14–53) 47 (38–56) 4 (3–8) < 0.0001
 Aortic valve regurgitation (degree) 1 (0–2) 1 (1–2) 1 (0–1) 0.01
 Mitral valve pressure gradient
  Maximal (mmHg) 7 (4–17) 4 (3–7) 17 (13–22) < 0.0001
  Mean (mmHg) 3 (1–6) 2 (1–3) 7 (6–11) < 0.0001
 Mitral valve regurgitation (degree) 2 (1–3) 1 (1–2) 3 (1–4) < 0.0001
 Tricuspid valve regurgitation (degree) 1 (0–2) 1 (0–1) 2 (1–3) < 0.0001
 Left ventricular ejection fraction (%) 55 (46–60) 60 (49–65) 52 (46–60) 0.04
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Table 2  Operative and postoperative characteristics and fibrinolytic parameters
Bold values used to visually identify significant p-values (<0.05)
Data shown as mean ± SD or as median (IQR), or number (percentage)
ACEI angiotensin-converting enzyme inhibitors, BMI Body Mass Index, ICU intensive care unit, PAI-1 plasminogen activator inhibitor-1, PAI-
1:Ag plasminogen activator inhibitor-1 antigen, PAP plasmin-α-2-antiplasmin complexes, TAFI thrombin-activatable fibrinolysis inhibitor, t50% 
time required for a 50% decrease in fibrin clot absorbance. Asterisk denotes that the values are based on a assessment of healthy controls evalu-
ated in our laboratory. The p-values refers to the comparison between patients with aortic stenosis and mitral stenosis
Variable Normal reference val-
ues (where applicable)
All patients (n = 121) Valve stenosis p Value
Aortic (n = 76) Mitral (n = 45)
Aortic cross-clamp time, min 72 (60–89) 74 (64–90) 62 (49–81) 0.004
CPB time, min 116 (95–143) 115 (98–144) 116 (84–142) 0.36
Biprosthesis, n (%) 52 (43) 48 (63) 4 (9) < 0.0001
Mechanical prosthesis, n (%) 69 (57) 28 (37) 41 (91) < 0.0001
Concomitant CABG, n (%) 18 (15) 13 (17) 5 (11) 0.27
Mitral valve repair 1 (1) 1 (1) 0 (0) 0.63
Tricuspid valve repair 6 (5) 0 (0) 6 (13) 0.002
Bicuspid aortic valve 26 (–) 26 (34) – –
Postoperative drainage after 12 h, mL 440 (333–628) 440 (350–620) 440 (300–640) 0.51
Rethoracotomy for bleeding, n (%) 7 (6) 6 (8) 1 (2) 0.21
ICU length of stay, days 1 (1–3) 1 (1–2) 1 (1–4) 0.22
In-hospital death, n (%) 7 (6) 3 (4) 4 (9) 0.23
Fibrinolytic parameters
 t50%, min 6.2–9.3* 14.1 (11.3–18.3) 12.6 (9.8–16.3) 16.2 (14.1–21.9) < 0.0001
 TAFI: Ag, IU/dL 56.0–105.0 100.6 (81.3–121.8) 92.8 (69.9–120.7) 112.4 (97.1–122.1) 0.005
 TAFI activity, µg/mL 19.9–29.1* 43.0 (37.0–48.8) 39.8 (32.3–47.5) 44.7 (41.1–50.3) 0.007
 TAFIa/TAFIai, ng/mL 3.0–10.0 14.9 (11.5–19.4) 15.7 (11.4–20.8) 14.2 (12.4–17.5) 0.29
 PAI-1:Ag, ng/mL 1.0–25.0 16.1 (10.5–25.1) 13.4 (9.8–19.5) 22.6 (16.1–29.7) 0.0001
 PAI-1 activity, IU/dL 7.0–26.7 10.9 (6.3–18.7) 10.3 (5.9–18.1) 12.7 (6.8–19.5) 0.37
 PAP, µg/mL 0.12–0.70 0.55 (0.47–0.64) 0.54 (0.44–0.67) 0.55 (0.47–0.64) 0.84
Platelet activation
 Platelet factor 4, ng/mL 94.7–100.0* 147.4 (135.0–159.5) 142.9 (132.9–155.4) 152.3 (139.1–165.7) 0.006
Fig. 1  Intergroup differences between patients with aortic and mitral stenosis  in  t50%, PAI-1 antigen and activity (panel a), and TAFI antigen, 
activity, and TAFIa/TAFIai (panel b)
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Preoperative fibrinogen was correlated with TAFI:Ag 
(r = 0.18, p = 0.047) and TAFIa/TAFIai (r = 0.25, p = 0.008). 
TAFIa/TAFIai was also associated with creatinine (r = 0.27, 
p < 0.004) and age (r = 0.45, p < 0.0001). In AV patients, 
patients with bicuspid aortic valve, compared with those with 
normal anatomy, apart from being younger (63 [60–67] vs. 
72 [64–76] years, respectively, p = 0.002), and having lower 
body mass index (26.0 [23.8–29.4] vs. 28.9 [26.4–32.0] 
kg/m2, respectively, p = 0.006), had lower TAFI activity 
(36.6 ± 11.0 vs. 43.3 ± 14.4%, respectively, p = 0.046), but 
did not differ regarding  t50% and other parameters.
Comorbidities
Patients with permanent AF (35 with MS and 5 with AS) 
had longer  t50% than individuals without documented AF 
(16.0 [13.1–22.6] vs. 13.1 [10.1–16.3] min, p = 0.0002) and 
higher PAI-1:Ag (23.4 [15.9–31.4] vs. 13.4 [9.7–19.4] ng/
mL, p < 0.0001). Patients with paroxysmal AF (n = 5) had 
higher PAI-1:Ag than individuals without documented AF 
(24.6 [19.0–25.2] vs. 13.4 [9.7–19.4] ng/mL, p = 0.03).
To verify the influence of MS on  t50% in the presence 
of persistent AF and VKA use, linear regression was uti-
lized. In univariate analysis, all variables were significant 
(MS: b = 4.91, adjusted  R2 = 0.17, p < 0.0001; AF: b = 2.54, 
adjusted  R2 = 0.06, p = 0.005; VKA: b = 4.50, adjusted 
 R2 = 0.14, p < 0.0001). In multivariate analysis (final model, 
adjusted  R2 = 0.18, p < 0.0001), only MS was the predictor 
of  t50% (b = 3.42, p = 0.01).
Surgical outcomes
There were no intergroup differences in the early mortality 
rate, re-exploration for bleeding and the length of ICU stay. 
The fatal cases (n = 7) did not differ from survivors with 
regard to TAFI and  t50%, but had lower PAI-1 activity (5.3 
[4.1–12.6] vs. 11.5 [6.5–19.3] IU/dL, respectively, p = 0.04).
A median postoperative chest tube drainage volume was 
440 ml with no AS–MS intergroup difference (Table 2.). 
In patients who required re-exploration for bleeding the 
median chest-tube output was more than twofold higher than 
in remaining patients (1120 [650–2000] vs. 420 [320–590] 
mL, respectively; p = 0.0002). In the whole group (n = 121) 
the postoperative drainage volumes correlated inversely 
with platelet count (r = − 0.29, p = 0.002), BMI (r = − 0.25, 
p = 0.007), fibrinogen (r = − 0.26, p = 0.006) and PAI-1:Ag 
(r = − 0.22, p = 0.02). Patients with high drainage volumes 
(≥ 1000 mL; n = 8, 7%), compared with those with lower 
volumes (n = 113) had lower PAI-1:Ag (by 40%, p = 0.02), 
but there were no differences in any other parameters.
Discussion
The novel finding of this study is that individuals suffering 
from MS (at the stage requiring surgical intervention) have 
more impaired global efficiency of fibrinolysis, compared 
with subjects with AS, as reflected by longer  t50%, higher 
activity of TAFI, and higher levels of PAI-1.
We report a positive association of  t50% with both maxi-
mal and mean transvalvular MV gradients, as well as with 
the degree of MR. We also observed the association of TAFI 
activity and PAI-1:Ag with transvalvular MV gradients. 
These associations point to the connection between MS and 
impairment of fibrinolysis.
While several tests to assess global plasma fibrinolytic 
activity are available, we used a plasma-based test, in which 
a thrombin-induced fibrin clot is lysed by exogenously added 
rt-PA at relatively high concentrations. This approach was 
successfully applied in previous papers [17, 18, 20, 21]. In 
contrast to the assay previously used by our group in AS 
patients [10], the current method does not use tissue factor, 
and the rtPA concentrations are higher. Based on previous 
reports,  t50% may be more sensitive to detect the impact of 
PAI-1 on fibrin clot properties [20]. Our findings supported 
this observation by showing that PAI-1:Ag is positively cor-
related with  t50% values.
In patients with VHD, we found that inhibition of fibrinol-
ysis was modulated most notably by the presence of AF, a 
prothrombotic condition, involving increased thrombin gen-
eration and fibrinogen concentrations [22, 23]. Marin et al. 
reported higher levels of PAI-1 in patients with MS who 
also had AF, as compared with MS patients in normal sinus 
rhythm [15]. We observed higher PAI-1 levels, along with 
prolonged  t50%, in subjects with AF (TAFI activity was unaf-
fected by AF, and modulated only by MS incidence). Our 
findings are in line with the recent paper by Drabik et al., 
who reported prolonged CLT and increased PAI-1 levels in 
subjects with non-valvular AF [24]. Impaired fibrinolysis, 
improved by oral anticoagulants, was also reported by other 
investigators exploring fibrinoysis in AF [25, 26]. Only few 
patients with progressed MS will present without AF, and 
AF contributes to blood stasis in the left atrium in the set-
ting of MV stenosis—another component in Virchow’s triad 
equation. The observation that even in MS patients AF is a 
potent enough factor to significantly alter fibrinolysis pro-
vides additional evidence for the necessity of anticoagula-
tion in this disorder. Nevertheless, MS was a predictor of 
 t50% independently of AF in this study.
The preoperative history of VKA therapy in both groups 
warrants a comment. While the groups differed regarding 
VKA use, it is unlikely that VKAs influenced the results 
of  t50% test, markedly elevated in MS patients. Previously, 
the permeability of the fibrin network was shown to rise in 
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parallel to elevations of INR and shortening of CLT in AF 
patients [25], thus, it could be expected that in the setting 
of VKA use,  t50% would be shorter. Also LMWHs prolong 
clot formation and increase the clot susceptibility to lysis 
[27], and as all anticoagulated patients in this study received 
LMWH bridging prior to operation,  t50% shortening could 
be expected. That notwithstanding, patients with MS, who 
in this study were most often subjected to anticoagulation, 
also had the most “prothrombotic” fibrin clot phenotype (and 
longest  t50%). One might speculate that the effects of VKAs 
and LMWHs on clot susceptibility to lysis are, arguably, 
abolished by MS and AF. On the other hand, our findings 
point to the importance of anticoagulation in MS, especially 
with concomitant AF. The prothrombotic state, as presented 
by us, is associated with MS, to some extent irrespectively of 
AF. Further studies are needed to verify the hypothesis that 
patients with advanced MS, but with no documented AF, 
would benefit from anticoagulant therapy, and to indicate 
which treatment modality would be most beneficial.
Furthermore, plasma PAI-1 was associated with enhanced 
bleeding after cardiac surgery in a study by Ozolina et al. on 
79 cardiosurgical patients (as few as 29 underwent valvular 
surgery) [28]. We demonstrated that plasma PAI-1:Ag is 
inversely correlated with chest-tube output. Yet, even with 
significant differences in PAI-1:Ag between AS and MS 
patients, we failed to show any differences in drainage vol-
umes. Our results confirm that fibrinolysis is a contributor 
to post-operative blood loss after cardiac surgery, but not 
potent enough to reveal clinical effects after elective valvular 
surgery. It should be mentioned that the bleeding tendency 
in AS [29] is largely driven by the imbalance in von Wille-
brand factor high molecular weight multimers [30]. In our 
study, the postoperative blood loss was also associated with 
preoperative fibrinogen level, PLT and BMI. Among the 
factors like fibrinogen or PLT, the cardiosurgical bleeding 
and transfusion risk scores consequently list low BMI/body 
weight as a risk factor [31]. Interestingly, PAI-1:Ag and BMI 
were positively associated in our study, and this association 
is in line with previous reports [32]. Inhibition of fibrinolysis 
has long been a target of strategies aimed at bleeding reduc-
tion in cardiac surgery, but there is no obvious consensus on 
the antifibrinolytic therapy in cardiac surgery. Our results 
suggest that different groups of patients might require a dif-
ferent antifibrinolytic regimen for optimal outcomes, with 
adjustment according to the diagnosis-dependent activity of 
fibrinolysis.
In the current report, along with  t50%, we studied TAFI, 
another important fibrinolysis inhibitor, using three assays 
[33]. This aspect of fibrinolyis was not studied yet in the 
context of VHD. TAFI:Ag measures all forms of TAFI in 
plasma: pro-TAFI, active and inactivated TAFI. TAFI:Act 
reflects only the active form of TAFI, while TAFIa/TAFIai 
reflects the ratio of active and inactivated TAFI levels (the 
latter: form of TAFI following the completion of its biologi-
cal function of C-terminal arginine and lysine cleavage from 
partially degraded fibrin). A novel observation in the current 
study is that the MS is associated with higher TAFI activity 
than AS, and this finding is independent of AF presence. 
The similar TAFIa/TAFIai values might be explained by 
“compensatory” changes in inactivated TAFI levels in both 
groups, leading to similar ratios. A role of TAFI in hypofi-
brinolysis in valvular disorders warrants further studies.
Limitations
The MS and AS groups are representative to patients in eve-
ryday practice, however they were not matched, and differed 
in some aspects. MS subjects are underrepresented, although 
this reflects the trends in open heart surgery, with a high 
prevalence of AS in patients requiring surgical intervention 
[6]. Still, small sample size of MS patients might be a reason 
for underpowering. Long term follow-up to seek for throm-
botic complications was beyond the scope of the current 
study. Despite sharing many risk factors [2, 5], degenerative 
AS and MS likely differ in the underlying pathology. Most 
MS patients had AF.
Conclusions
We demonstrated that degenerative MS is associated with 
more pronounced impairment of global fibrinolytic capac-
ity than AS at the stage of surgical intervention. AF likely 
contributes to fibrinolysis impairment in MS, but the role 
of fibrinolysis in valvular disorders in terms of progression 
of the disease and thromboembolic complications requires 
further studies. The relationship between the preoperative 
fibrinolysis activation, antifibrinolytic treatment, and postop-
erative outcomes in cardiac surgery needs to be investigated.
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